^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR L861Q

    i
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
    Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (ORBITAL) (NCT04233021)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    02/03/2025
    Initiation :
    07/16/2020
    Primary completion :
    03/15/2023
    Completion :
    12/27/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (AZENT) (NCT02841579)
    Phase 2
    MedSIR
    Completed
    Last update posted :
    01/28/2025
    Initiation :
    09/02/2016
    Primary completion :
    12/01/2018
    Completion :
    02/14/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (U31402-A-U102) (NCT03260491)
    Phase 1
    Daiichi Sankyo
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    10/30/2017
    Primary completion :
    03/31/2026
    Completion :
    12/31/2026
    ALK • ROS1
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X
    |
    patritumab deruxtecan (U3-1402)
    Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib (NCT02364609)
    Phase 1
    Jonathan Riess
    Completed
    Last update posted :
    10/16/2024
    Initiation :
    09/30/2015
    Primary completion :
    04/26/2018
    Completion :
    05/01/2020
    PD-L1
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    Keytruda (pembrolizumab) • erlotinib • Gilotrif (afatinib)
    A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET) (NCT05526755)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    03/06/2023
    Primary completion :
    04/05/2029
    Completion :
    04/05/2029
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (NCI-2019-05913) (NCT04085315)
    Phase 1
    Collin Blakely
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/12/2019
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L
    |
    Tagrisso (osimertinib) • alisertib (MLN8237)
    Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/11/2016
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (NCT05546866)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    02/21/2023
    Primary completion :
    06/30/2029
    Completion :
    06/30/2029
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (EXCLAIM-2) (NCT04129502)
    Phase 3
    Takeda
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    01/10/2020
    Primary completion :
    12/30/2024
    Completion :
    12/30/2024
    HER-2
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    cisplatin • carboplatin • pemetrexed • Exkivity (mobocertinib)
    Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCI-2021-04325) (NCT04940299)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    09/23/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRAF
    |
    EGFR mutation • BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q • EGFR T790M negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Actemra IV (tocilizumab)
    Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC (NCT05805631)
    Phase 2
    Taipei Veterans General Hospital, Taiwan
    Not yet recruiting
    Last update posted :
    05/01/2024
    Initiation :
    06/01/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • pemetrexed
    Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer (NCT05401110)
    Phase 1
    Karen Reckamp, MD, MS
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    09/15/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • carotuximab IV (ENV-105)
    A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer (NCT05514496)
    Phase 1
    Nalo Therapeutics Inc.
    Recruiting
    Last update posted :
    03/25/2024
    Initiation :
    10/05/2022
    Primary completion :
    02/17/2027
    Completion :
    10/17/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR L861Q
    |
    NX-019
    A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (Balise) (NCT01897480)
    Phase 2
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    03/01/2024
    Initiation :
    08/28/2013
    Primary completion :
    03/14/2016
    Completion :
    12/31/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    |
    erlotinib • emibetuzumab (LY2875358)
    Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer (NCT04780568)
    Phase 1
    Ohio State University Comprehensive Cancer Center
    Recruiting
    Last update posted :
    12/11/2023
    Initiation :
    01/18/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    EGFR • NOTCH3
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib) • tegavivint (BC2059)
    A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (EXCLAIM) (NCT02716116)
    Phase 1/2
    Takeda
    Active, not recruiting
    Last update posted :
    10/18/2023
    Initiation :
    06/16/2016
    Primary completion :
    03/28/2025
    Completion :
    03/28/2025
    HER-2
    |
    EGFR mutation • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • EGFR L861R • HER-2 exon 23 mutation
    |
    carboplatin • pemetrexed • Exkivity (mobocertinib)
    A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations (KCSG-LU15-09) (NCT03434418)
    Phase 2
    Duke University
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    06/30/2018
    Primary completion :
    10/12/2022
    Completion :
    10/12/2022
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (NCT03468985)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    05/07/2018
    Primary completion :
    05/09/2022
    Completion :
    12/21/2022
    EGFR • PD-L1 • ALK • RET • ROS1
    |
    EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer (NCT06067776)
    Phase 1
    Jonathan Riess
    Not yet recruiting
    Last update posted :
    10/05/2023
    Initiation :
    01/01/2024
    Primary completion :
    01/01/2025
    Completion :
    11/01/2026
    HER-2 • BRAF • ALK • MET • RET
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)
    Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations (NCT04790409)
    Phase 2
    Zhejiang Cancer Hospital
    Completed
    Last update posted :
    09/14/2023
    Initiation :
    08/01/2019
    Primary completion :
    09/13/2023
    Completion :
    09/13/2023
    PD-L1
    |
    EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR L861Q + EGFR S768I
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001) (NCT06029816)
    Phase 2
    Convalife (Shanghai) Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/08/2023
    Initiation :
    11/20/2023
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    EGFR
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 18 mutation
    |
    Nerlynx (neratinib)
    Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance (NCT04545710)
    Phase 2
    University of California, San Diego
    Active, not recruiting
    Last update posted :
    08/08/2023
    Initiation :
    11/21/2020
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib) • Verzenio (abemaciclib)
    Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05168566)
    Phase 2b
    Teligene US
    Recruiting
    Last update posted :
    05/22/2023
    Initiation :
    09/01/2022
    Primary completion :
    08/01/2024
    Completion :
    02/01/2025
    EGFR
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719X + EGFR S768I
    |
    sutetinib (SZMD4)
    YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations (NCT05767892)
    Phase 3
    Suzhou Puhe Pharmaceutical Technology Co., LTD
    Not yet recruiting
    Last update posted :
    04/05/2023
    Initiation :
    05/01/2023
    Primary completion :
    07/30/2025
    Completion :
    12/31/2026
    HER-2
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    cisplatin • carboplatin • pemetrexed • PH001
    Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer (NCT05267288)
    Phase 2
    Qingdao Central Hospital
    Recruiting
    Last update posted :
    03/29/2023
    Initiation :
    02/01/2021
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    EGFR
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Gilotrif (afatinib)
    Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer (BEVERLY) (NCT02633189)
    Phase 3
    National Cancer Institute, Naples
    Active, not recruiting
    Last update posted :
    03/24/2023
    Initiation :
    04/01/2016
    Primary completion :
    12/01/2023
    Completion :
    07/01/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
    |
    Avastin (bevacizumab) • erlotinib
    Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR (NCT05767866)
    Phase 1/2
    Suzhou Puhe Pharmaceutical Technology Co., LTD
    Recruiting
    Last update posted :
    03/17/2023
    Initiation :
    03/30/2018
    Primary completion :
    12/30/2023
    Completion :
    05/30/2024
    EGFR
    |
    EGFR mutation • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    PH001
    Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND) (NCT04811001)
    Phase 2
    Fondazione Ricerca Traslazionale
    Recruiting
    Last update posted :
    02/21/2023
    Initiation :
    06/12/2020
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    EGFR • HER-2 • BRAF • ALK • MET • ROS1
    |
    EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR L861Q • ALK mutation • ROS1 rearrangement • MET mutation • EGFR S768I • EGFR G719A • EGFR G719S • EGFR G719C
    |
    Tagrisso (osimertinib) • Vizimpro (dacomitinib)
    Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer (NCT05445310)
    Phase 2
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    02/16/2023
    Initiation :
    08/06/2022
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L858R + EGFR S768I
    |
    Ivesa (firmonertinib)
    First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation (NCT05548348)
    Phase 2
    Chongqing University Cancer Hospital
    Recruiting
    Last update posted :
    09/21/2022
    Initiation :
    09/26/2022
    Primary completion :
    12/31/2023
    Completion :
    10/31/2025
    EGFR
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Ivesa (firmonertinib)
    Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC (NCT05536505)
    Phase 2
    Guangdong Association of Clinical Trials
    Recruiting
    Last update posted :
    09/14/2022
    Initiation :
    09/13/2022
    Primary completion :
    10/01/2025
    Completion :
    10/01/2030
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 19 deletion + EGFR L861Q
    Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations (NCT05507606)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Recruiting
    Last update posted :
    08/19/2022
    Initiation :
    08/01/2021
    Primary completion :
    08/01/2023
    Completion :
    08/01/2024
    EGFR • TP53
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • carboplatin • pemetrexed • Byvasda (bevacizumab biosimilar)
    the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy (NCT05497076)
    Phase N/A
    Fujian Cancer Hospital
    Not yet recruiting
    Last update posted :
    08/11/2022
    Initiation :
    09/01/2022
    Primary completion :
    01/01/2024
    Completion :
    07/01/2024
    CDKN2A • RB1 • CCND1 • CCNE1 • CDK4 • CDKN2B • CCND2 • CCND3
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation
    |
    AiRuiKang (dalpiciclib)
    Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer (ACE-Lung) (NCT02716311)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    08/11/2022
    Initiation :
    05/01/2016
    Primary completion :
    02/01/2019
    Completion :
    04/07/2021
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Erbitux (cetuximab) • Gilotrif (afatinib)
    A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (NCT05068024)
    Phase 1/2
    Forward Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    07/26/2022
    Initiation :
    08/23/2021
    Primary completion :
    10/30/2022
    Completion :
    12/30/2025
    EGFR • HER-2
    |
    EGFR mutation • HER-2 mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation • HER-2 A775
    |
    FWD1509
    E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C (EPICAL) (NCT03623750)
    Phase 1/2
    Instituto Oncológico Dr Rosell
    Completed
    Last update posted :
    06/30/2022
    Initiation :
    07/06/2018
    Primary completion :
    03/26/2020
    Completion :
    12/14/2021
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR exon 18 mutation
    |
    cyclophosphamide • CimaVax EGF (EGF-PTI) • cyclophosphamide intravenous
    Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations (LU21-16) (NCT05277701)
    Phase 2
    Yonsei University
    Not yet recruiting
    Last update posted :
    03/14/2022
    Initiation :
    04/01/2022
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR L747S • EGFR E709A
    |
    Lazcluze (lazertinib)